<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00528450</url>
  </required_header>
  <id_info>
    <org_study_id>07-108</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>MSKCC-07108</secondary_id>
    <secondary_id>CEPHALONO-MSKCC-07108</secondary_id>
    <nct_id>NCT00528450</nct_id>
  </id_info>
  <brief_title>Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia</brief_title>
  <official_title>Phase II Study of Combined All-Trans Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Tretinoin may help cancer cells become more like normal cells, and to grow and
      spread more slowly. Drugs used in chemotherapy, such as arsenic trioxide and idarubicin, work
      in different ways to stop the growth of cancer cells, either by killing the cells or by
      stopping them from dividing. Giving tretinoin together with arsenic trioxide with or without
      idarubicin may kill more cancer cells.

      PURPOSE: This phase II trial is studying how well giving tretinoin together with arsenic
      trioxide with or without idarubicin works in treating patients with acute promyelocytic
      leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the rate of molecular remission after induction therapy comprising
           tretinoin (ATRA) and arsenic trioxide (ATO) (along with idarubicin in patients with
           leukocytosis) in patients with acute promyelocytic leukemia (APL).

      Secondary

        -  To determine the rate of clinical complete remission and the time to remission after
           induction therapy.

        -  To determine the proportion of patients in molecular remission after each course of
           postremission therapy and to use these findings to direct the number of consolidation
           courses with ATRA and idarubicin that are administered.

        -  To determine the disease-free survival and overall survival of patients treated with
           this regimen.

        -  To determine the toxicity of this treatment regimen, including the number and length of
           hospitalizations, the incidence of secondary myelodysplastic syndromes or acute myeloid
           leukemia, and the effects of treatment on LVEF.

        -  To characterize the differentiation of APL cells during treatment with combined ATRA and
           ATO using serial immunophenotyping studies of peripheral blood and bone marrow.

        -  To compare the results of quantitative real-time reverse transcriptase-polymerase chain
           reaction (RT-PCR) assays performed on bone marrow and peripheral blood.

      OUTLINE:

        -  Induction therapy: Patients receive tretinoin orally twice daily and arsenic trioxide IV
           over 1-4 hours once daily until a marrow remission is documented or for 60 days,
           whichever comes first. Patients with leukocytosis (WBC &gt; 10,000/μL) also receive
           idarubicin IV over 10-15 minutes beginning on day 2 and continuing every other day for 4
           doses. Patients who achieve a clinical complete remission (CR) proceed to consolidation
           therapy. If a marrow remission is not achieved after 60 days, the patient is removed
           from the study.

        -  Consolidation therapy:

             -  Consolidation courses 1, 2, and 3: Beginning 3-6 weeks after documentation of
                clinical CR, patients receive consolidation therapy comprising tretinoin orally
                twice daily for 15 days and arsenic trioxide IV over 1-4 hours once daily 5 days a
                week for 5 weeks. Consolidation therapy repeats every 3-6 weeks for 3 courses.

      Patients who have a negative PML-RARα transcript by reverse transcriptase-polymerase chain
      reaction (RT-PCR) assay after consolidation course 2 proceed to maintenance therapy after
      receiving consolidation course 3. Patients who have a negative PML-RARα transcript by RT-PCR
      assay after consolidation course 3, proceed to consolidation course 4 followed by maintenance
      therapy. Patients who have a positive PML-RARα transcript by RT-PCR assay after consolidation
      courses 2 and 3 proceed to consolidation courses 4 and 5.

        -  Consolidation course 4: Beginning 3-6 weeks after completion of consolidation course 3,
           patients receive tretinoin orally twice daily for 15 days and idarubicin IV over 10-15
           minutes once daily for 4 days.

        -  Consolidation course 5: Beginning 3-6 weeks after completion of consolidation course 4,
           patients receive tretinoin orally twice daily for 15 days and idarubicin IV over 10-15
           minutes once daily for 3 days.

      Patients who remain positive for the PML-RARα transcript after 5 courses of consolidation
      therapy are removed from the study. Patients who have a negative PML-RARα transcript after 5
      courses of consolidation therapy proceed to maintenance therapy.

        -  Maintenance therapy: Beginning approximately 3 months after completion of the final
           consolidation course, patients receive tretinoin orally twice daily for 15 days.
           Treatment repeats every 3 months for up to 2 years.

      Disease status will be monitored with serial analyses of bone marrow and peripheral blood
      samples using RT-PCR for PML-RARα mRNA. Patients will be followed until relapse, death, loss
      to follow-up, or removal from study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of accrual
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Molecular Remission Rate</measure>
    <time_frame>2 years</time_frame>
    <description># of patients with Complete Remission</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Tretinoin and Arsenic Trioxide With or Without Idarubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Outline for details</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arsenic trioxide</intervention_name>
    <arm_group_label>Tretinoin and Arsenic Trioxide With or Without Idarubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
    <arm_group_label>Tretinoin and Arsenic Trioxide With or Without Idarubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tretinoin</intervention_name>
    <arm_group_label>Tretinoin and Arsenic Trioxide With or Without Idarubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Morphologic diagnosis of acute promyelocytic leukemia (APL), confirmed by one of the
             following:

               -  Demonstration of t(15;17) using conventional cytogenetics or fluorescence in situ
                  hybridization (FISH)

               -  Positive PML-RARα transcript by reverse transcriptase-polymerase chain reaction
                  (RT-PCR) assay

          -  Patients with CNS involvement by APL are eligible

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 60-100%

          -  Creatinine ≤ 2.0 mg/dL or creatinine clearance &gt; 60 mL/min

          -  Bilirubin &lt; 2.0 mg/dL (unless attributed to Gilbert disease)

          -  Alkaline phosphatase ≤ 2.5 times the upper limit of normal (ULN)

          -  AST and ALT ≤ 2.5 ULN

          -  LVEF ≥ 50% on echocardiogram or MUGA scan

          -  QTc ≤ 500 msec on baseline ECG

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for ≥ 4 months after the
             completion of study treatment

          -  No active serious infections not controlled by antibiotics

          -  No other concurrent active malignancy requiring immediate therapy

          -  No clinically significant cardiac disease (New York Heart Association class III or IV
             heart disease), including chronic arrhythmias

          -  No pulmonary disease

          -  No other serious or life-threatening condition deemed unacceptable by the principal
             investigator

        PRIOR CONCURRENT THERAPY:

          -  No prior treatment for APL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph G. Jurcic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Maslak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2007</study_first_submitted>
  <study_first_submitted_qc>September 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2007</study_first_posted>
  <results_first_submitted>December 23, 2015</results_first_submitted>
  <results_first_submitted_qc>December 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 29, 2016</results_first_posted>
  <last_update_submitted>December 23, 2015</last_update_submitted>
  <last_update_submitted_qc>December 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute promyelocytic leukemia (M3)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Arsenic trioxide</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Patients</title>
          <description>Tretinoin and Arsenic Trioxide With or Without Idarubicin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Patients</title>
          <description>Tretinoin and Arsenic Trioxide With or Without Idarubicin</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Molecular Remission Rate</title>
        <description># of patients with Complete Remission</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>Tretinoin and Arsenic Trioxide With or Without Idarubicin</description>
          </group>
        </group_list>
        <measure>
          <title>Molecular Remission Rate</title>
          <description># of patients with Complete Remission</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Patients</title>
          <description>Tretinoin and Arsenic Trioxide With or Without Idarubicin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC-3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Head/headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain - Pain NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Glucose, high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Phosphate, low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Potassium, high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration - Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Peter Maslak</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>212-639-5518</phone>
      <email>maslakp@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

